DJIA 17,012.07 29.48 0.17%
NASDAQ 4,455.59 10.68 0.24%
S&P 500 1,979.15 0.24 0.01%
market minute promo

Synageva BioPharma (NASDAQ: GEVA)

70.97 1.67 (2.41%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

GEVA $70.97 2.41%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $69.55
Previous Close $69.30
Daily Range $69.55 - $70.54
52-Week Range $44.52 - $119.42
Market Cap $2.3B
P/E Ratio -17.24
Dividend (Yield) $0.00 (0.0%)
Volume 11,332
Average Daily Volume 329,423
Current FY EPS -$5.93

Sector

Healthcare

Industry

Drugs

Synageva BioPharma (GEVA) Description

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of a new class of antiviral drug treatments called fusion inhibitors. Website: http://www.synageva.com/

News & Commentary Rss Feed

3 Stocks to Get on Your Watchlist

A beaten-up national insurer, a small-cap oil and gas company operating overseas, and a potentially overvalued biopharmaceutical company are this week's must-watch stocks.

Sector Update: Health Care

Sector Update: Health Care Stocks Following Broader Markets Highers; GlycoMimetics Jumps More Than 1

Sector Update: Health Care Stocks Following Broader Markets Highers; GlycoMimetics Jumps More Than 10% After Naming Cancer-Specialist to Board

Synageva Shares Tumble Amid Positive Phase 3 Data, A Director's 75% Gain & Analyst Concerns

Synageva's Sebelipase Alfa Meets Primary Endpoint in ARISE - Analyst Blog

Synageva BioPharma Reports Phase 3 Study Meets Primary Endpoint And Six Secondary Endpoints Across M

Synageva BioPharma Reports Phase 3 Study Meets Primary Endpoint And Six Secondary Endpoints Across Multiple Disease-Related Abnormalities

GEVA: Insiders Vs. Shorts

Synageva's Q1 Loss Narrower than Expected - Analyst Blog

Synageva Heading For Big Disappointment

Should You Get Rid of Synageva BioPharma (GEVA) Now? - Tale of the Tape

UPDATE: Morgan Stanley Reiterates on Synageva BioPharma as Brain-Blood Barrier Study is Good Next St

UPDATE: Morgan Stanley Reiterates on Synageva BioPharma as Brain-Blood Barrier Study is Good Next Step

See More GEVA News...

GEVA's Top Competitors

GEVA $70.97 (2.41%)
Current stock: GEVA
AMGN $122.82 (0.14%)
Current stock: AMGN
GILD $92.10 (0.70%)
Current stock: GILD
BIIB $339.78 (1.01%)
Current stock: BIIB